Drugs Made In America Acquisition II Corp. (DMII)
NASDAQ: DMII · Real-Time Price · USD
9.99
0.00 (0.00%)
At close: Apr 2, 2026, 4:00 PM EDT
9.99
-0.01 (-0.05%)
After-hours: Apr 2, 2026, 4:00 PM EDT
Company Description
Drugs Made In America Acquisition II Corp. does not have significant operations.
It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Drugs Made In America Acquisition II Corp.
| Country | United States |
| Founded | 2024 |
| IPO Date | Sep 25, 2025 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Roger Bendelac |
Contact Details
Address: 1 East Broward Boulevard, Suite 700 Fort Lauderdale, Florida 33301 United States | |
| Phone | 954 870 3099 |
Stock Details
| Ticker Symbol | DMII |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 2040475 |
| CUSIP Number | G2851K104 |
| ISIN Number | KYG2851K1040 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Roger Bendelac | Chief Executive Officer |
| Saleem Elmasri CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |
| Nov 18, 2025 | 10-Q | Quarterly Report |
| Nov 18, 2025 | 8-K | Current Report |
| Nov 17, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 2, 2025 | 8-K | Current Report |
| Oct 2, 2025 | SCHEDULE 13D | Filing |
| Sep 29, 2025 | 8-K | Current Report |